Azelnidipine

Azelnidipine
Clinical data
Trade names	CalBlock,AZUSA,Azovas
AHFS/Drugs.com	International Drug Names
Routes of; administration	Oral
ATC code	none;
Legal status
Legal status	In general: ℞ (Prescription only);
Identifiers
	IUPAC name 3-1-Benzhydryl-3-azetidinyl 5-isopropyl 2-amino-6-methyl-4-(m-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate;
CAS Number	123524-52-7 ;
PubChem CID	65948;
ChemSpider	59352 ;
UNII	PV23P19YUG;
KEGG	D01145 ;
ChEMBL	ChEMBL1275868 ;
CompTox Dashboard (EPA)	DTXSID3020120 ;
ECHA InfoCard	100.162.151
Chemical and physical data
Formula	C33H34N4O6
Molar mass	582.657 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES [O-][N+](=O)c1cccc(c1)C5C(/C(=O)OC(C)C)=C(\NC(\N)=C5\C(=O)OC4CN(C(c2ccccc2)c3ccccc3)C4)C;
	InChI InChI=1S/C33H34N4O6/c1-20(2)42-32(38)27-21(3)35-31(34)29(28(27)24-15-10-16-25(17-24)37(40)41)33(39)43-26-18-36(19-26)30(22-11-6-4-7-12-22)23-13-8-5-9-14-23/h4-17,20,26,28,30,35H,18-19,34H2,1-3H3 ; Key:ZKFQEACEUNWPMT-UHFFFAOYSA-N ;
	(what is this?) (verify)

Azelnidipine (INN; marketed under the brand name CalBlock — カルブロック) is a dihydropyridine calcium channel blocker. Azelnidipine is L and T calcium channel blocker. It is sold in Japan by Daiichi-Sankyo pharmaceuticals, Inc. Unlike nicardipine, it has a gradual onset and has a long-lasting antihypertensive effect, with little increase in heart rate. Drug Controller General Of India (DCGI) has approved the use of azelnipine in India. It is launched under the brand name Azusa (ajanta pharma ltd.)^[1] In 2020.

References

^ Oizumi K, Nishino H, Koike H, Sada T, Miyamoto M, Kimura T (September 1989). "Antihypertensive effects of CS-905, a novel dihydropyridine Ca++ channel blocker". Jpn. J. Pharmacol. 51 (1): 57–64. doi:10.1254/jjp.51.57. PMID 2810942.^{Scholar search} Archived 2021-09-30 at the Wayback Machine

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.

[pmid2810942-1] Oizumi K, Nishino H, Koike H, Sada T, Miyamoto M, Kimura T (September 1989). "Antihypertensive effects of CS-905, a novel dihydropyridine Ca++ channel blocker". Jpn. J. Pharmacol. 51 (1): 57–64. doi:10.1254/jjp.51.57. PMID 2810942.^{Scholar search} Archived 2021-09-30 at the Wayback Machine

[1]